Twist Bioscience ( (TWST) ) has released its Q4 earnings. Here is a breakdown of the information Twist Bioscience presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Twist Bioscience is a synthetic biology and genomics company known for its disruptive DNA synthesis platform, which offers synthetic DNA-based products for various industries, including healthcare and agriculture. In its fiscal year 2024, Twist Bioscience reported a record revenue of $313.0 million, marking a 28% increase from the previous year. The company also achieved a gross margin improvement to 42.6% for the year, with a notable 45.1% in the fourth quarter. The company’s strong performance is attributed to its growing portfolio, including the Express portfolio and NGS tools, as well as the successful launch of new products such as the Gene Fragments and the FlexPrep™ Kit. Despite a net loss of $208.7 million for the year, Twist Bioscience’s adjusted EBITDA improved significantly from the previous year, emphasizing its focus on achieving adjusted EBITDA breakeven. Looking forward, Twist Bioscience expects continued revenue growth in fiscal 2025, aiming for a revenue range of $367 million to $377 million and a gross margin of approximately 48%. The company remains committed to investing in research and development to drive precision and scalability in its products.